Mandate

Vinge advises Cinclus Pharma in connection with a capital raising

Vinge has advised the pharmaceutical development company Cinclus Pharma in connection with a capital raising of approximately SEK 250 million by way of a directed share issue to several new investors and current shareholders.

The purpose of the share issue is to fund the further clinical development of X842, a clinical-stage drug candidate for the treatment of gastroesophageal reflux disease (GERD).

Vinge’s team consisted primarily of Dain Hård Nevonen, Kristina Ekberg, Amanda Knutsson and Fredric Reissmüller.

Related

Vinge advises Workday, Inc. on its $1.1 billion acquisition of Sana Labs

Vinge, together with Orrick Herrington & Sutcliffe, has advised Workday, Inc. (NASDAQ: WDAY) (“Workday”) on its acquisition of all shares in Sana Labs AB.
September 16, 2025

Vinge advises on the sale of ArmaTech to Defensor Group

Vinge has advised on the sale of ArmaTech i Kungsbacka AB (“ArmaTech”) to the newly formed defence group Defensor Group AB (“Defensor”).
September 16, 2025

Vinge advisor in connection with Klarna's IPO on the New York Stock Exchange

Vinge, together with Latham & Watkins, acted as advisor to bookrunners and managers in connection with the listing of Klarna, the global digital bank and provider of flexible payment solutions, on the New York Stock Exchange.
September 15, 2025